◆ Almost €6bn raised across seven tranches ◆ 12 years is the 'sweet spot' for supply ◆ Single digit concessions offered

◆ Deal is first from updated sustainability bond framework and follows social debut from 2025 ◆ Earlier return to euros than previous years ◆ Minimal concession paid

More convertibles expected after strong fund performance

◆ Deal is heard more than 12.5 times subscribed despite slim, if any, concession ◆ Investors 'scrambling to get more risk' ◆ New trade precedes 10 year covered bond and follows $3.3bn triple-tranche Yankee

Experienced banker joins from Helaba

Mobimo and Kraftwerke Oberhasli bring green bonds

Implementation necessary after wide-ranging changes last year

Bank's head of DCM and syndicate chief talk bond market expansion plans

Loans bankers wary of potential overbuilding amid Europe data centre growth

Scope of UK regulation set to be more restricted than EU equivalent

German government will spend €108bn on military next year

Taxonomy alignment and credible transition plans could be more important for issuers

Country saw surge in syndicated lending volumes in 2025 and this year is expected to be just as strong

$450m add-on makes deal more efficient

First exclusively Estonian securitization the European Investment Bank has supported

Debt financing to become more sophisticated as the race to build data centres across Europe heats up

JP Morgan sole bookrunner on first jumbo block in a month

This week Tom Hall and Thomas Hopkins discuss how Enpal's return heated up the ABS market and take the CLO equity market's temperature

Solutions exist but political will is necessary

It will take years and huge amounts of money to get Venezuela in a state to restructure its debt

Oil reforms are needed for debt repayment to restart, but will be difficult to accomplish

The International Finance Facility for Immunisation (IFFIm) was set up in 2006 to provide funding to Gavi, the Vaccine Alliance, itself a public/private sector partnership, to expedite the vaccination of children in the poorest countries against endemic infectious diseases. Doris Herrera-Pol, IFFIm board member and former director of global capital markets at the World Bank, spoke to GlobalCapital about the role the capital markets can play in the development and deployment of a Covid-19 vaccine.

Investors have got a fever, and the only cure is more pharma. Biotech equity issuance is surging, in line with rising stock prices in the secondary market, as stock pickers pan for the company that will cure Covid-19, among other maladies. But this is more speculating than investing and many are going to catch a cold chasing around a risky sector that is starting to look a lot like the dot-com bubble.

Freeline Theraputics, the UK gene therapeutics company, has filed to list in the US on the Nasdaq exchange, continuing the trend of biotech companies seeking to raise capital in the equity capital markets.